Our mission is to abolish kidney cancer as a threat to the life and health of patients by supporting patient advocacy and research by supporting government and industry research funding, facilitating research collaborations, and offering direct financial support for clinical and laboratory researchers with promising ideas. Together, we can find the cure.
District Days: How to Be an Advocate from Home
KidneyCAN is excited to present our plan for at-home advocacy this summer. In August, when our congressional representatives will be at home in their districts, we are making a plan for our community to engage in District Days.
District Days will give the kidney cancer community an opportunity to share their stories and experiences with their representatives. This communication is vital to the process of securing funding for kidney cancer research.
Please plan to join us! We want all our participants to feel safe and will conduct the training sessions virtually via Zoom. Your in-person participation will be limited to one face-to-face meeting with your congressperson, with masks and social distancing for safety.
You don’t need to be a trained advocate, and you won’t need any special tools or skills. You just need a passion for our cause. We’ll help with the rest! Register using the form below.
Proceeds from our Rock the Cure events have been used to explore exciting approaches to generate individualized vaccines for kidney cancer patients. The approach will use fresh biopsies from kidney cancer patients to accurately represent their current cancer immune profile. The cells are then cultured and multiplied using a novel cell culture technique and can serve in the future as the basis for a patient specific whole cell or RNA vaccine. The advantage of this approach is that it not only directs the immune system to the specific mutations of the tumor, but also other over expressed common and rare normal proteins and activated retroviruses. Thus, the full repertoire of targets for the immune system will be displayed. While vaccines in the past have been met with moderate benefit at best, they are now poised to synergize with the modern immunotherapy revolution of immune checkpoint inhibitors.
My death sentence was commuted by something called RADVAX — a clinical trial in its second phase being run by Dr. Hans Hammers, a recent Johns Hopkins transplant to UT Southwestern. The trial is being funded by KidneyCAN.
From Our Blog
Funded major projects to date include:
RADVAX investigator led immunotherapy trial for 25 advanced kidney cancer patients at UT Southwestern combining Nivolumab, Ipilimumab and SBRT.
Support of UT Southwestern’s Kidney Cancer Research Program. 1 of only 2 SPOREs (Specialized Programs of Research Excellence) for Kidney Cancer in the US.
Our primary sources of support are donations from the general public and fundraising.
[wd_hustle id=”email” type=”embedded”]